QST Qingdao Saber Technology Pharmaceutical
Vials tend to hold more than the label (median +7.3%); 0 of 11 vials were more than 10% under.
For research use only. VendorVerify sells nothing and takes no money from vendors. No affiliate links, no coupon codes, no paid rankings. How scores work
Every vial we have on file
- Within ±5% / purity 99%+
- 5–20% under, overfilled / purity 95–99%
- Failed: over 20% under, over 50% over, empty or under 95% pure
Dose vs label
11 vials measured · 0 emptyPurity
22 vials measured- Median purity
- 99.64%
- across 22 vials
- Median dose vs label
- +7.3%
- across 11 vials; + means more than the label
- Failed vials
- 0.0%
- 0 of 22 vials; the rate weights each lab report equally and recent reports more, as the score does
- Lab reports
- 13
- Jun 6, 2025 to Aug 24, 2026
Labs: Janoshik, Peptide Test, Uzorak
Key facts
- VendorVerify holds third-party lab results for 22 QST vials from 13 lab reports, dated Jun 2025 to Aug 2026.
- 0 of 22 QST vials failed: empty, under 95% pure, more than 20% under the label or more than 50% over it.
- The median QST vial tested at 99.64% purity across 22 vials with a purity result.
- The median QST vial held +7.3% compared with its label across 11 vials where the lab measured the amount.
- Buyers have had 5 different compounds from QST lab tested.
- QST ranks #3 of 30 ranked vendors on the VendorVerify score.
- QST vials on file were tested by Janoshik, Peptide Test, Uzorak.
By peptide
| Peptide | Vials | Failed | Median purity | Median dose vs label | Dose vs label, −20% to +20% |
|---|---|---|---|---|---|
| Retatrutide | 14 | 0 | 99.59% | +10.6% | |
| Tirzepatide | 3 | 0 | 99.67% | +7.3% | |
| BPC-157 | 2 | 0 | 99.54% | +5.7% | |
| Tesamorelin | 2 | 0 | 99.64% | — | — |
| Ipamorelin | 1 | 0 | 99.90% | −4.7% |
Lab reports
One row per tested vial, newest first.
| Date | Peptide | Lab | Label | Measured | Dose vs label | Purity |
|---|---|---|---|---|---|---|
| Aug 24, 2026 | RetatrutideBatch R1026Ja01 COA labeled wrong | Janoshik | — | 10.75 mg | — | 99.42% |
| Aug 24, 2026 | RetatrutideBatch R1026Ja01 COA labeled wrong | Janoshik | — | 10.68 mg | — | 99.44% |
| Aug 24, 2026 | RetatrutideBatch R1026Ja01 COA labeled wrong | Janoshik | — | 10.71 mg | — | 99.51% |
| Jun 30, 2026 | RetatrutideBatch R30 25Ja01 | Janoshik | 30 mg | 33.17 mg | +10.6% | 99.71% |
| Jun 30, 2026 | RetatrutideBatch R30 25Ja01 | Janoshik | 30 mg | 34.27 mg | +14.2% | 99.70% |
| May 7, 2026 | BPC-157Batch BP1025Ja01 | Janoshik | 10 mg | 10.57 mg | +5.7% | 99.61% |
| May 7, 2026 | BPC-157Batch BP1025Ja01 | Janoshik | 10 mg | 10.57 mg | +5.7% | 99.46% |
| Apr 17, 2026 | RetatrutideBatch T60 608050-1/5/2026 | Uzorak | 10 mg | 11.79 mg | +17.9% | 99.93% |
| Apr 16, 2026 | TesamorelinBatch T3025Ja01 | Janoshik | — | 10.77 mg | — | 99.64% |
| Apr 16, 2026 | TesamorelinBatch 18800-1 Tesamorelin | Janoshik | — | — | — | 99.64% |
Other lab tests
Endotoxin, TFA, counterion and contaminant checks, as reported by the lab. They are shown for transparency and are not part of the score.
| Date | Peptide | Test | Result | Lab |
|---|---|---|---|---|
| Aug 25, 2026 | RetatrutideBatch R1026Ja01 (COA labeled wrong) | Endotoxin | <10 EU/Vial (1.635 EU/Vial estimate) | Janoshik |
| Jul 1, 2026 | RetatrutideBatch R30 25Ja01 | Endotoxin | 10.975 EU/Vial. | Janoshik |
| May 22, 2026 | BPC-157Batch BPC 10 BP1025Ja01 | Endotoxin | 89.468 EU/Vial. | Janoshik |
| Apr 28, 2026 | IpamorelinBatch IPA 1025Ja01 | Sterility | TAMC=Pass, TYMC=Pass | Janoshik |
| Apr 24, 2026 | Unidentified sampleBatch Unknown | Endotoxin | <10 EU/Vial (3.712 EU/Vial estimate) | Janoshik |
| Apr 21, 2026 | TirzepatideBatch T3025Ja01 | Sterility | TAMC=Fail, TYMC=Fail | Janoshik |
| Apr 20, 2026 | TesamorelinBatch TE1025Ja01 | Endotoxin | 2.277 EU/Vial | Janoshik |
| Apr 14, 2026 | IpamorelinBatch IPA 1025Ja01 | Endotoxin | 1.620 EU/Vial. | Janoshik |
| Apr 14, 2026 | RetatrutideBatch R30 Purple Caps | Endotoxin | <10 EU/Vial (9.741 EU/Vial estimate) | Janoshik |
| Apr 9, 2026 | RetatrutideBatch R30 Purple caps | LCMS | Mannitol, retatrutide and degradation products | Janoshik |
QST: common questions
Is QST legit?
We can't vouch for any vendor as a business, and we don't sell or recommend products. What we can show is what buyers' independent lab tests found: 0 of 22 QST vials on file failed, meaning they were empty, under 95% pure, more than 20% under the label or more than 50% over it. That places QST #3 of 30 ranked vendors, above market on our score. Results on file run from Jun 2025 to Aug 2026.
Has QST been third-party tested?
Yes. We hold results for 22 QST vials from 13 lab reports, tested by Janoshik, Peptide Test, Uzorak. Each result comes from a lab report a buyer paid for, not from a certificate the vendor supplied.
Are QST vials dosed correctly?
Across 11 vials where the lab measured the amount, the median QST vial held +7.3% compared with its label. 0 of 11 held more than 10% less than the label said.
How pure is QST?
The median QST vial tested at 99.64% purity across 22 vials with a purity result. We count anything under 95% as a failed vial, and a vial at 99.5% or higher gets full marks for purity.
Does QST pay to be listed or ranked?
No. VendorVerify sells nothing and takes no money from vendors. No affiliate links, no coupon codes, no paid rankings. A vendor's place comes only from lab results.
Will my QST vial match these results?
Not necessarily. A lab report describes the vials that were tested, and batches differ. A clean record lowers the odds of a bad vial but doesn't rule one out, which is why newer reports count for more in the score.
Vendor Reviews
Bought from this vendor?
Sign in to write a review. Every review comes from a verified phone number and a real purchase.